Elf5 inhibits TGF-β-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation

Prostate

Volumn 75, Issue 8, 2015, Pages 872-882

  Yao, Bing ^a   Zhao, Jinsheng ^b   Li, Yalin ^a   Li, Hui ^a   Hu, Zhaojun ^c   Pan, Pan ^a   Zhang, Yiran ^a   Du, E ^a   Liu, Ranlu ^a   Xu, Yong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN NANKAI HOSPITAL   (China)

^c Hujiayuan Street Community Health Service Centre   (China)

Author keywords

Elf5; EMT; prostate cancer; TGF

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; DECAPENTAPLEGIC PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF 5; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ELF5 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS;

AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; DROSOPHILA; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MORPHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STAINING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DISEASE COURSE; FOLLOW UP; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FOLLOW-UP STUDIES; HEK293 CELLS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84927794919     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22970     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9-29.
2. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA,. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 2009; 119 (6): 1438-1449.
3. Thiery JP, Acloque H, Huang RY, Nieto MA,. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139 (5): 871-890.
4. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29 (34): 4741-4751.
5. Zhou ZJ, Dai Z, Zhou SL, Hu ZQ, Chen Q, Zhao YM, Shi YH, Gao Q, Wu WZ, Qiu SJ, Zhou J, Fan J,. HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. Cancer Res 2014; 74 (10): 2750-2762.
6. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA,. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145 (6): 926-940.
7. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9 (4): 265-273.
8. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119 (6): 1420-1428.
9. Wodarz A, Nathke I,. Cell polarity in development and cancer. Nat Cell Biol 2007; 9 (9): 1016-1024.
10. Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ,. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol 2012; 10 (12): e1001461.
11. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukacisin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y,. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol 2012; 14 (11): 1212-1222.
12. Chakrabarti R, Wei Y, Romano RA, DeCoste C, Kang Y, Sinha S,. Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells 2012; 30 (7): 1496-1508.
13. Lee JM, Dedhar S, Kalluri R, Thompson EW,. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172 (7): 973-981.
14. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM,. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17 (11): 3091-3100.
15. Moustakas A, Heldin CH,. Dynamic control of TGF-beta signaling and its links to the cytoskeleton. FEBS Lett 2008; 582 (14): 2051-2065.
16. Millet C, Zhang YE,. Roles of Smad3 in TGF-beta signaling during carcinogenesis. Crit Rev Eukaryot Gene Expr 2007; 17 (14): 281-293.
17. Jinnin M, Ihn H, Tamaki K,. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006; 69 (2): 597-607.
18. Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM,. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-beta-driven epithelial-mesenchymal transition. Cancer Discov 2013; 3 (10): 1172-1189.
19. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA,. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133 (4): 704-715.
20. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E,. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10 (19): 2462-2477.
21. Hemberger M, Udayashankar R, Tesar P, Moore H, Burton GJ,. ELF5-enforced transcriptional networks define an epigenetically regulated trophoblast stem cell compartment in the human placenta. Hum Mol Genet 2010; 19 (12): 2456-2467.
22. Ng RK, Dean W, Dawson C, Lucifero D, Madeja Z, Reik W, Hemberger M,. Epigenetic restriction of embryonic cell lineage fate by methylation of Elf5. Nat Cell Biol 2008; 10 (11): 1280-1290.
23. Lee HJ, Hinshelwood RA, Bouras T, Gallego-Ortega D, Valdes-Mora F, Blazek K, Visvader JE, Clark SJ, Ormandy CJ,. Lineage specific methylation of the Elf5 promoter in mammary epithelial cells. Stem Cells 2011; 29 (10): 1611-1619.
24. Hilton HN, Kalyuga M, Cowley MJ, Alles MC, Lee HJ, Caldon CE, Blazek K, Kaplan W, Musgrove EA, Daly RJ, Naylor MJ, Graham JD, Clarke CL, Ormandy CJ,. The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5. Mol Endocrinol 2010; 24 (7): 1380-1392.
25. Menzies KK, Lee HJ, Lefevre C, Ormandy CJ, Macmillan KL, Nicholas KR,. Insulin, a key regulator of hormone responsive milk protein synthesis during lactogenesis in murine mammary explants. Funct Integr Genomics 2010; 10 (1): 87-95.
26. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M, Smalley MJ,. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008; 9: 591.
27. Escamilla-Hernandez R, Chakrabarti R, Romano RA, Smalley K, Zhu Q, Lai W, Halfon MS, Buck MJ, Sinha S,. Genome-wide search identifies Ccnd2 as a direct transcriptional target of Elf5 in mouse mammary gland. BMC Mol Biol 2010; 11: 68.
28. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ,. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 2008; 22 (5): 581-586.
29. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A,. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112 (10): 1486-1494.
30. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders KC,. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17 (1-2): 19-27.